We investigated the clinical significance of IgG β2-glycoprotein I (GPI)-dependent anticardiolipin antibodies (aCL) in rheumatic diseases. Three hundred and seventeen patients were entered. They consisted of 133 patients with SLE, 60 with RA, 45 with SSc, 37 with PM, 23 with overlap syndrome (overlap), and 19 with unclassified connective tissue disease (UCTD). IgG β2-GPI-dependent aCL were examined by ELISA. While IgG β2-GPI-dependent aCL were detected in 13% of patients with SLE, these aCL were positive in two patients with SSc, two with overlap and 14 with UCTD. A significant association between IgG β2-GPI-dependent aCL and thrombosis was found. Clinical manifestations were studied in 32 patients with secondary APS based on SLE and 14 with primary APS (PAPS). Incidences of malar rash, arthritis, renal disorder, leucopenia, immunological disorders and hypocomplementemia were significantly less frequent in patients with PAPS. IgG β2-GPI-dependent aCL were detected in all patients with PAPS and in 34% of secondary APS. This difference was significant. These data suggest that IgG β2-dependent aCL are useful for identifying a subset in patients with APS.
HughesGRVHarrisENGharaviAE. The anticardiolipin syndrome. J Rheumatol1986; 13: 486–9.
3.
Alarcón-SegoviaDDelezéMOriaCV. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine1989; 68: 353–65.
4.
LovePESantoroSA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med1990; 112: 682–98.
5.
GhavariAEHarrisENAshersonRA. Anticardiolipin antibodies: Isotype distribution and phospholipid specificity. Ann Rheum Dis1987; 46: 1–6.
6.
McNeilHPSimpsonRJChestermanCN. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA1990; 87: 4120–4.
7.
GalliMComfuriusPMaassenC. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet1990; 335: 1544–7.
8.
MatsuuraEIgarashiYFujimotoM. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet1990; 336: 177–8.
9.
MatsuuraEIgarashiYFujimotoM. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol1992; 148: 3885–91.
10.
GalliMComfuriusPBarbuiT. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost1992; 68: 297–300.
11.
OrdiJSelvaAMonegalF. Anticardiolipin antibodies and dependence of a serum cofactor. A mechanism of thrombosis. J Rheumatol1993; 20: 1321–4.
12.
HarrisENGharaviAEPatelSP. Evaluation of the anticardiolipin antibody test: Report of an international workshop held on 4 April 1986. Clin Exp Immunol1987; 68: 215–22.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–7.
15.
ArnettFCEdworthySMBlochDA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988; 31: 315–24.
16.
Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum1980; 23: 581–90.
17.
BohanAPeterJBBowmanRL. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine1977; 56: 255–86.
18.
ViannaJLKhamashtaMAOrdi-RosJ. Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients. Am J Med1994; 96: 3–9.
19.
TakiMIkedaYHandaM. Role of antiphospholipid antibodies in the pathogenesis of thrombosis in antiphospholipid syndrome. Acta Haematol Jpn1990; 53: 1620–9.
HarrisENChanJKHAshersonRA. Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med1986; 146: 2153–6.
22.
MatsuuraEIgarashiYYasudaT. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med1994; 179: 457–62.
23.
CohnenG. Immunochemical quantitation of β2-glycoprotein I in various diseases. J Lab Clin Med1970; 75: 212–6.
24.
ShiWChongBHChestermanCN. β2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: Differences with lupus anticoagulants. Blood1993; 81: 1255–62.
25.
NimpfJBeversEMBomansPHH. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I. Biochim Biophys Acta1986; 884: 142–9.
26.
NimpfJWurmHKostnerGM. β2-glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis1987; 63: 109–14.
27.
AshersonRAKhamashtaMAOrdi-RosJ. The ‘primary’ antiphospholipid syndrome: Major clinical and serological features. Medicine1989; 68: 366–74.
28.
Mackworth-YoungCGLoizouSWalportMJ. Primary antiphospholipid syndrome: Features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis1989; 48: 362–7.
29.
PietteJ-CWechslerBFrancesC, Systemic lupus erythematosus and the antiphospholipid syndrome: Reflections about the relevance of ARA criteria. J Rheumatol1992; 19: 1835–7.
30.
EhrensteinMRSwanaMKeelingD. Anti-DNA antibodies in the primary antiphospholipid syndrome (PAPS). Br J Rheumatol1993; 32: 362–5.
31.
AshersonRA. SLE and the antiphospholipid antibody syndrome. J Rheumatol1993; 20: 1801–2.
OostingJDDerksenRHWMBobbinkIWG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenic mechanism?Blood1993; 81: 2618–25.
